Skip to content
Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » Advocacy » ENETS session – High grade classification

ENETS session – High grade classification

  • March 26, 2019

(by Meredith Cummins, NSW Project Officer)

The 16th ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumour Disease was a wonderful opportunity to network internationally and gain knowledge and insight into the great work being done in this field. There were so many fabulous sessions, so many that it was difficult to report on them all. The session below was part of the ENETs / European Society of Pathology (ESP) New Classification / Making Sense of High-grade Neoplasms. Within this session Dr Jean – Yves Scoazec from France presented Pulmonary and Digestive High Grade NENs – Where are they similar? The following highlights the grading and a conclusion of the grading. So much work is being done to better define the respective NETs so that treatment can be customized for better management.

WHO classification of digestive NENs (2019) is divided into-

  • Neuroendocrine tumour G1 – differentiation  – well differentiated, mitotic index ,2 mitoses / 2mm2, Ki 67 Index <= 2% (Low Grade)
  • Neuroendocrine tumour G2 – differentiation – well differentiated ,mitotic index 2-20 mitoses / 2mm2, Ki 67 Index – 3-20 % (Intermediate Grade)
  • Neuroendocrine G3 – differentiation – well differentiated, mitotic index  20 mitoses / 2 mm2, Ki 67 index >20% (High Grade)
  •  Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index >20% (High to very High Grade)
  • Small cell neuroendocrine carcinoma – differentiation  – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index  > 20% (High to very High Grade)

Next WHO classification of Lung NENs (20..)

  • Typical Carcinoid – differentiation  – well differentiated, necrosis  – absent, Mitotic index , 2 mitoses / 10HPF (2mm2)( Low Grade)
  • Atypical carcinoid – well differentiated, necrosis – possible, focal, mitotic index – 2-10 mitoses / 10HPF (2mm2) (Intermediate Grade)
  • Supracarcinoid – differentiation – well differentiated – (High Grade)
  • Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, necrosis – frequent, extensive, mitotic index  >10mitoses/ 10HPF (2mm2) – (High to very High Grade)
  • Small Cell neuroendocrine carcinoma – differentiation  – poorly differentiated, necrosis  – frequent, extensive, mitotic index > 10 mitoses / 10HPF (2mm2) – (High to very High Grade)

So in conclusion :

  • Lung and digestive high grade NENs share some similarities but they also express site specific feature
  • High grade NETs exist in both the digestive system and the lung: they require an accurate diagnosis and probably, an adapted treatment
  • Small Cell neuroendocrine carcinoma is a distinctive entity
  • Large Cell neuroendocrine carcinoma is a diverse category with a need for a reevaluation of our diagnostic and therapeutic approaches

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

World Cancer Day 2023

January 10, 2023

Support Groups Christmas Gatherings

December 20, 2022

NeuroEndocrine Cancer Australia & Norman Family Trust Partnership

December 14, 2022

NeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online Wills

December 14, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousPetition update
NextLet’s BE FAIR with government cancer fundingNext

Related Posts

World Cancer Day 2023

World Cancer Day: a leading international awareness day to “Close the Care Gap” World Cancer Day held on 4 February every year is the global

NeuroEndocrine Cancer Australia & Norman Family Trust Partnership

NeuroEndocrine Cancer Australia are delighted to announce a new donor partnership. The Norman Family Bequest are funding a NET Nurse Educator in memory of Will

NeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online Wills

NeuroEndocrine Cancer Australia have partnered with Gathered Here, Australia’s most-trusted end-of-life services site, to offer our supporters a free online will. We are constantly looking

NET Cancer Day 2022

November 10 was NET Cancer Day, a day for all neuroendocrine cancer patients, carers, families and healthcare professionals to unite and help raise awareness of

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative